RWD Study in HER2+ mBC Patients in Third-Line Therapy

Inclusion Criteria

• •Male or female patients (≥18 years of age)
• •Patients with stage IV breast cancer
• •Patients with HER2+ status in metastatic setting
• •Patients that received at least two lines of active anti-cancer drugs due to disease progression.
• •Patients that began third-line therapy prior to October 31, 2018.